Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents

References

• Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J. Infect. Dis.164, 731–740 (1991).
   PubMed Web of Science ®Google Scholar
• Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis.32, 358–366 (2001).
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Kuchar RT, Rex JH et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin. Infect. Dis.33, 1871–1878 (2001).
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Stratton SL, Dignani MC et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin. Infect. Dis.34, 780–789 (2002).
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Stratton SL, Dignani MC et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin. Infect. Dis.35, e86–e88 (2002).
   Web of Science ®Google Scholar
• Offidani M, Corvatta L, Olivieri A et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant.24, 1079–1087 (1999).
   PubMed Web of Science ®Google Scholar
• Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant.28, 265–271 (1996).
   Google Scholar
• Auner HW, Sill H, Mulabecirovic A et al. Infectious complications after autologous haematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann. Hematol.81, 374–377 (2002).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Salonen J, Juvonen E et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur. J. Haematol.73, 174–178 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mold infections in haematopoietic stem cell transplant recipients. Clin. Infect. Dis.34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant.19, 801–808 (1997).
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis.175, 1459–1466 (1997).
   PubMed Web of Science ®Google Scholar
• Hagen EA, Stern H, Porter D et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin. Infect. Dis.36, 9–15 (2003).
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic haematopoietic stem cell transplants after nonmyeloablative conditioning. Blood102, 827–933 (2003).
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol.116, 475–482 (2002).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100, 4358–4366 (2002).
   PubMed Web of Science ®Google Scholar
• Singh N. Interactions between viruses in transplant recipients. Clin. Infect. Dis.40, 430–436 (2005).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol.39, 3254–3259 (2001).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Messer SA et al. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and E test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J. Clin. Microbiol.41, 1440–1446 (2003).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Merz WG, Rinaldi MG et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother.37, 1847–1849 (1993).
   PubMed Web of Science ®Google Scholar
• Marr KA, White TC, van Burik JA et al. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis.25, 908–910 (1997).
   PubMed Web of Science ®Google Scholar
• CDC; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among haematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant.6, 659–713 (2000).
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med.326, 845–851 (1992).
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective randomized, double-blind study. J. Infect. Dis.171, 1545–1552 (1995).
   PubMed Web of Science ®Google Scholar
• Marr KA, Siedel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood96, 2055–2061 (2000).
   PubMed Web of Science ®Google Scholar
• Antifungal drugs. Treat Guidel. Med. Lett.3(30), 7–14 (2005).
   PubMedGoogle Scholar
• Micafungin (Mycamine®) for fungal infections. Med. Lett.47, 51–52 (2005).
   Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36, 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet362, 1142–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood12(5), 552–559 (2006).
   Web of Science ®Google Scholar
• Marty FM, Laury CM, Cutler CS. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.36, 2708–2709 (2004).
   Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother.41, 2326–2332 (1997).
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.Antimicrob. Agents Chemother.46, 3001–3012 (2002).
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin. Infect. Dis.42, 1171–1178 (2006).
   PubMed Web of Science ®Google Scholar
• Powles MA, Liberator P, Anderson J et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother.42, 1985–1989 (1998).
   PubMed Web of Science ®Google Scholar
• van Burik JAH, Ratanatharathorn V, Stepan D et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing haematopoietic stem cell transplantation. Clin. Infect. Dis.39, 1407–1416 (2004).
   PubMed Web of Science ®Google Scholar
• De Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis.39, 842–849 (2004).
   PubMed Web of Science ®Google Scholar
• Trenschel R, Ditschkowski M, Elmaagacgli AH et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant.35, 583–586 (2005).
   PubMed Web of Science ®Google Scholar
• Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis.6, 110–116 (2004).
   PubMedGoogle Scholar
• Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant.34, 13–20 (2004).
   PubMed Web of Science ®Google Scholar
• Martino R, Nomdedeu J, Altes A. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant.13, 265–269 (1994).
   PubMed Web of Science ®Google Scholar
• Kruger WH, Russmann B, de Wit M et al. Haematopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol.113, 104–108 (2005).
   PubMed Web of Science ®Google Scholar
• Mehta P, Augustson B, Krishnamurthy S et al. Successful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection. Bone Marrow Transplant.34, 825–826 (2004).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant.33, 943–948 (2004).
   PubMed Web of Science ®Google Scholar
• Cornely O, Maertens J, Winston D et al. Posaconazole vs standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: results of a randomized, multicenter trial. Program and abstracts of the 47th American Society of Hematology. GA, USA, Abstract 1844 (2005).
   Google Scholar
• Cornely OA, Maertens J, Winston D et al. Posaconazole vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome: impact on mortality. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, Abstract M-722b (2005).
   Google Scholar
• Diekema DJ, Messer SA, Hollis RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol.41, 3623–3626 (2003).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Nihtinen A, Volin L et al. Candidemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. Bone Marrow Transplant.34, 891–895 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA. Issues in the design of fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39(Suppl. 4), S170–S175 (2004).
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind, placebo-controlled study. Bone Marrow Transplant.23, 163–168 (1999).
   PubMed Web of Science ®Google Scholar
• Tollemar J, Ringden O, Andersson B et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant.12, 577–582 (1993).
   PubMed Web of Science ®Google Scholar
• Barrett JP, Vardulaki KA, Conlon C. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther.25, 1295–1320 (2003).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Pranatharthi H et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann. Intern. Med.138, 705–713 (2002).
   Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood103, 1527–1533 (2004).
   PubMed Web of Science ®Google Scholar
• Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann. Hematol.71, 311–312 (1995).
   PubMed Web of Science ®Google Scholar
• Gillies J, Hung K, Fitzsimons E et al. Severe vincristine toxicity in combination with itraconazole. Clin. Lab. Haematol.20, 123–124 (1998).
   PubMedGoogle Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole vs. fluconazole for the prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: results of a multicenter trial. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, Abstract M-716 (2005).
   Google Scholar
• Buell DB, Kovanda D, Drake T et al. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, Abstract M-719 (2005).
   Google Scholar
• Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother.49, 1331–1336 (2005).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis.191, 1350–1360 (2005).
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med.26, 950–952 (2004).
   Google Scholar
• Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis.39, 584–587 (2004).
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis.39, 743–746 (2004).
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Morin O, Moreau P et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin. Infect. Dis.40, e35–e37 (2005).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Moleti ML, Micozzi A et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J. Clin. Microbiol.43, 5395–5396 (2005).
   PubMed Web of Science ®Google Scholar
• Safdar A, O’Brien S, Kouri IF. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant.34, 467–468 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351, 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Pavie J, Lacroix C, Hermoso DG et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J. Clin. Microbiol.43, 4902–4904 (2005).
   PubMed Web of Science ®Google Scholar
• Alexander BD, Schell WA, Miller JL et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation80, 868–871 (2005).
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Zygomycosis: re-emergence of an old pathogen. Clin. Infect. Dis.39, 588–590 (2004).
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis.41, 634–653 (2005).
   PubMed Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis.5, 775–785 (2005).
   PubMed Web of Science ®Google Scholar
• Tobon AM, Arango M, Fernandez D et al. Mucormycosis (zygomycosis) in a heart–kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis.36, 1488–1491 (2003).
   PubMed Web of Science ®Google Scholar
• van Burik JA, Hare RS, Solomon HF et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis.42, e61–e65 (2006).
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis.39, 797–802 (2004).
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer97, 1025–1032 (2003).
   PubMed Web of Science ®Google Scholar